Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system(BDDCS)

被引:0
|
作者
LI Ji [1 ]
Caroline A.Larregieu [2 ]
Leslie Z.Benet [2 ]
机构
[1] Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
[2] Department of Bioengineering & Therapeutic Science, University of California
关键词
Biopharmaceutics Drug Disposition Classification System(BDDCS); Natural products(NPs); Dose number; Solubility and extent of metabolism;
D O I
暂无
中图分类号
R915 [药物生物学];
学科分类号
1007 ;
摘要
Natural products(NPs) are compounds that are derived from natural sources such as plants, animals, and microisms. Therapeutics has benefited from numerous drug classes derived from natural product sources. The Biopharmaceutics Drug position Classification System(BDDCS) was proposed to serve as a basis for predicting the importance of transporters and enzymes in determining drug bioavailability and disposition. It categorizes drugs into one of four biopharmaceutical classes according to their water solubility and extent of metabolism. The present paper reviews 109 drugs from natural product sources: 29% belong to class 1(high solubility, extensive metabolism), 22% to class 2(low solubility, extensive metabolism), 40% to class 3(high solubility, poor metabolism), and 9% to class 4(low solubility, poor metabolism). Herein we evaluated the characteristics of NPs in terms of BDDCS class for all 109 drugs as wells as for subsets of NPs drugs derived from plant sources as antibiotics. In the 109 NPs drugs, we piled 32 drugs from plants, 50%(16) of total in class 1, 22%(7) in class 2 and 28%(9) in class 3, none found in class 4; Meantime, the antibiotics were found 5(16%) in class 2, 22(71%) in class 3, and 4(13%) in class 4; no drug was found in class 1. Based on this classification, we anticipate BDDCS to serve as a useful adjunct in evaluating the potential characteristics of new natural products.
引用
收藏
页码:888 / 897
页数:10
相关论文
共 50 条
  • [31] Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of Class I drugs
    Khan, M. Zahirul I.
    Rausl, Dragica
    Radosevic, Senka
    Filic, Darko
    Danilovski, Aleksandar
    Dumic, Mijenko
    Knezevic, Zdravka
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2006, 58 (11) : 1475 - 1482
  • [32] Computational Models to Assign Biopharmaceutics Drug Disposition Classification from Molecular Structure
    Akash Khandelwal
    Praveen M. Bahadduri
    Cheng Chang
    James E. Polli
    Peter W. Swaan
    Sean Ekins
    Pharmaceutical Research, 2007, 24 : 2249 - 2262
  • [33] Computational models to assign biopharmaceutics drug disposition classification from molecular structure
    Khandelwal, Akash
    Bahadduri, Praveen M.
    Chang, Cheng
    Polli, James E.
    Swaan, Peter W.
    Ekins, Sean
    PHARMACEUTICAL RESEARCH, 2007, 24 (12) : 2249 - 2262
  • [34] pH-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery
    Varma, Manthena V.
    Gardner, Iain
    Steyn, Stefanus J.
    Nkansah, Paul
    Rotter, Charles J.
    Whitney-Pickett, Carrie
    Zhang, Hui
    Di, Li
    Cram, Michael
    Fenner, Katherine S.
    El-Kattan, Ayman F.
    MOLECULAR PHARMACEUTICS, 2012, 9 (05) : 1199 - 1212
  • [35] Hepatic Clearance Predictions from In Vitro-In Vivo Extrapolation and the Biopharmaceutics Drug Disposition Classification System
    Bowman, Christine M.
    Benet, Leslie Z.
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (11) : 1731 - 1735
  • [36] Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts
    Camenisch, Gian P.
    PHARMACEUTICAL RESEARCH, 2016, 33 (11) : 2583 - 2593
  • [37] Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts
    Gian P. Camenisch
    Pharmaceutical Research, 2016, 33 : 2583 - 2593
  • [38] Biopharmaceutics Classification System-Based Biowaivers for Generic Oncology Drug Products: Case Studies
    Tampal, Nilufer
    Mandula, Haritha
    Zhang, Hongling
    Li, Bing V.
    Nguyen, Hoainhon
    Conner, Dale P.
    AAPS PHARMSCITECH, 2015, 16 (01): : 5 - 9
  • [39] Biopharmaceutics Classification System-Based Biowaivers for Generic Oncology Drug Products: Case Studies
    Nilufer Tampal
    Haritha Mandula
    Hongling Zhang
    Bing V. Li
    Hoainhon Nguyen
    Dale P. Conner
    AAPS PharmSciTech, 2015, 16 : 5 - 9
  • [40] Effect of the Similarity of Formulations and Excipients of Approved Generic Drug Products on In Vivo Bioequivalence for Putative Biopharmaceutics Classification System Class III Drugs
    Ren, Ping
    Chan, Theresa
    Yang, Wen-Cheng
    Frost, Mitchell
    Wang, Yan
    Luke, Markham
    Kim, Myong-Jin
    Lionberger, Robert
    Zhang, Yi
    PHARMACEUTICS, 2023, 15 (09)